VCP R191Q

# Research Brief: VCP R191Q Variant ## Pathogenic Mechanisms The VCP R191Q variant represents a pathogenic mutation in the valosin-containing protein (VCP), a critical AAA+ ATPase involved in protein quality control, autophagosome maturation, and aggresome assembly. This variant disrupts VCP's core molecular functions, including ATP binding and hydrolysis activity, which are essential for its role in extracting ubiquitinated proteins from cellular compartments. Literature findings demonstrate that R191Q triggers hypoxic stress responses specifically in astrocytes and causes widespread protein quality control dysfunction through impaired VCP-mediated protein clearance pathways. The variant's impact on HIF-1α signaling suggests a novel pathogenic mechanism involving cellular stress responses. Given VCP's extensive interactome with protein quality control machinery (ASPSCR1, NSFL1C, UBXN family proteins), the R191Q substitution likely propagates dysfunction across multiple proteostasis networks, affecting ATP-dependent protein extraction and autophagy flux. ## Clinical Significance The R191Q variant is pathogenic and causally linked to inclusion body myopathy with Paget's disease and frontotemporal dementia (IBMPFD), as well as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Notably, this variant expands the phenotypic spectrum of VCP-related diseases, with documented cases presenting with semantic dementia—a distinct clinical manifestation from typical IBMPFD. Clinical initiatives have established baseline data collection protocols for R191Q carriers, enabling longitudinal tracking of disease progression patterns across the multisystem manifestations. This is particularly significant given the variable age of onset and phenotypic heterogeneity observed in VCP-related disorders. The establishment of natural history parameters will be critical for identifying early biomarkers, optimizing timing of supportive interventions, and measuring therapeutic responses in future clinical trials. ## Therapeutic Landscape Therapeutic development for VCP R191Q targets the protein's aggregation propensity and enzymatic function. Structural analysis identifies a high-scoring aggregation hotspot at residues 265-269 (score: 0.80), representing a critical therapeutic target region. The computationally-generated candidate peptide CP-VCP-001 specifically targets this 265-269 region, designed to prevent pathogenic protein aggregation that may result from the R191Q substitution's destabilizing effects. The therapeutic rationale centers on two complementary approaches: (1) preventing aberrant protein aggregation through peptide-based inhibition of the identified hotspot, and (2) modulating HIF-1α signaling and VCP-dependent protein clearance pathways revealed by mechanistic studies. The variant's disruption of ATP-dependent functions suggests that small molecules targeting nucleotide binding or enhancing residual ATPase activity may provide additional therapeutic benefit. ## Research Directions Critical knowledge gaps remain regarding R191Q-specific pathogenic mechanisms. Priority research directions include: (1) structural characterization of how the R191Q substitution affects the VCP hexamer assembly and nucleotide-dependent conformational changes using the updated AlphaFold models; (2) validation of CP-VCP-001 peptide efficacy in patient-derived cellular models to assess aggregation prevention and functional rescue; (3) comprehensive mapping of how R191Q alters VCP interactions with its extensive partner network (UBXN proteins, NSFL1C), particularly under stress conditions; (4) investigation of genotype-phenotype correlations explaining the semantic dementia presentation versus typical IBMPFD manifestations; and (5) development of biomarkers leveraging the established baseline data collection to enable early intervention. The emerging role of astrocyte-specific hypoxic stress responses warrants cell-type-specific therapeutic strategies that may differ from approaches targeting muscle or neuronal pathology.